|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No significant differences were identified between patients with mutated versus nonmutated WTX with respect to gender (45% versus 33% male), age (mean 3.9 versus 4.1 years), tumor size (mean 12.7 cm versus 12.8 cm), anaplasia (9% versus 12%), rhabdomyoblastic differentiation (18% versus 8%), cartilage differentiation (9% versus 4%), mucinous epithelial differentiation (9% versus 4%), nephrogenic rests (28% versus 21%), or relapse rate (11% versus 25%).
|
28326956 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A knock-in mouse line conditionally expressing the tumor suppressor WTX/AMER1.
|
28960679 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28.
|
25882849 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In silico and experimental validation in independent datasets confirmed the existence of functional mutations in AMER1 in approximately 10% of analyzed colorectal cancer tumors.
|
26071483 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results indicate that WTX inactivation occurs in a wider variety of tumor types than previously appreciated and point to shared pathogenic mechanisms between a subset of pediatric malignancies.
|
24249259 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
WTX is also known as a tumor suppressor gene, and somatic mutations in that gene have been identified in Wilms tumors.
|
24459086 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Group 1 tumors (63%) were defined as 11p15-mutant and WT1-normal; a third also had WTX mutations.Group 2 tumors (13%) were WT1-mutant.
|
22470196 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recently, mutations were reported in WTX at Xq11.1 in Wilms' tumors.
|
22800892 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants.
|
20956941 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although mutations in known tumor-associated genes (WT1, WTX, and CATNB) occur only in a third of tumors, many tumors show evidence of activated β-catenin-dependent Wnt signaling, but the molecular mechanism by which this occurs is unknown.
|
21983638 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genes identified as being mutated in Wilms' tumour include TP53, a classic tumour suppressor gene (TSG); CTNNB1 (encoding β-catenin), a classic oncogene; WTX, which accumulating data indicate is a TSG; and WT1, which is inactivated in some Wilms' tumours, similar to a TSG.
|
21248786 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the remaining three tumours, the WTX mutation was present in the tumour only indicating late acquisition of these mutations.
|
20679664 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have identified FOXP3 and WTX as two X-linked tumor suppressor genes that are somatically inactivated by single genetic hits.
|
20434787 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both APC and WTX are involved in Wnt/β-catenin pathway regulation and may play a role in ACT tumorigenesis.
|
20978149 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One of the questions about the WTX gene is whether the genetic alterations of the WTX gene are specific to only Wilms' tumors.
|
18720004 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
WTX has been reported to play a role in the WNT/beta-catenin signaling pathway, and, interestingly, WTX deletion/truncation mutations appeared to be rare in tumors carrying exon 3 mutations of CTNNB1, encoding beta-catenin.
|
18311776 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings indicate that previously reported estimates on the proportion of Wilms' tumors due to WTX alterations should be reconsidered.
|
18391980 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data provide a possible mechanistic explanation for the tumor suppressor activity of WTX.
|
17510365 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The discovery of an X chromosome gene, WTX, that is mutated somatically in approximately 30% of Wilms tumors is notable both for helping to explain the genetic etiology of a substantial proportion of tumors and also for underscoring the role that X chromosome genes can play in cancer genetics.
|
17292822 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast to biallelic inactivation of autosomal tumor-suppressor genes, WTX is inactivated by a monoallelic "single-hit" event targeting the single X chromosome in tumors from males and the active X chromosome in tumors from females.
|
17204608 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
High-resolution array comparative genomic hybridization (array CGH) analysis of tumor DNA revealed a 1.5 Mb chromosome deletion encompassing the WTX gene at Xq11.
|
17620295 |
2007 |